CD20 Products

Antibodies
Antibody Pairs
CD20 Antibody Pair
CD20 Antibody Pair
H00000931-AP22
Species: Hu
Applications: S-ELISA
Host: Polyclonal
Lysates
CD20 Overexpression Lysate
CD20 Overexpression Lysate
NBL1-13312
Species: Hu
Applications: WB
CD20 Overexpression Lysate
CD20 Overexpression Lysate
NBL1-13311
Species: Hu
Applications: WB
Proteins
Recombinant Human CD20 GST (N ...
Recombinant Human CD20 GST (N-Term...
H00000931-P01
Species: Hu
Applications: WB, ELISA, PA, AP
Recombinant Human CD20 His Pr ...
Recombinant Human CD20 His Protein
NBP2-61455
Species: Hu
Applications: PAGE
CD20 Recombinant Protein Anti ...
CD20 Recombinant Protein Antigen
NBP1-90052PEP
Species: Hu
Applications: AC

Description

CD20 is a non-glycosylated phosphoprotein that is expressed on the surface of normal and malignant B cells and functions in mediating calcium transport and B cell differentiation (1,2). CD20 is encoded by the membrane-spanning 4-domain family A member 1 (MS4A1) gene and, in humans, is located on chromosome 11q12 (1). The CD20 protein is 297 amino acids (aa) in length with a theoretical molecular weight (MW) of 33 kDa (1,2). Structurally, the CD20 protein has four membrane-spanning domains, two extracellular loop domains, and intracellular N- and C-terminal domains (1,2). CD20 is expressed at specific stages of B cell maturation including pre-B cells, mature naive and activated B cells, and memory B cells, but is absent from plasmablasts and plasma cells (1,3,4). Expression of CD20 is often increased on malignant B cells associated with various B cell disorders such as chronic lymphocytic leukemia (CLL), multiple sclerosis (MS), and rheumatoid arthritis (2-4). Anti-CD20 monoclonal antibody (mAb)-based therapies have become an appealing target for treating these immune-related disorders and cancers (1-5). Rituximab, a chimeric mAb, was the first FDA approved CD20 monoclonal antibody for the treatment of non-Hodgkin's lymphoma that is now commonly used to treat MS (2,3). Since its initial approval in 1997, several other chimeric and humanized anti-CD20 mAbs have been developed including Ofatumumab, Ublituximab, and Obinutuzumab (1-5). B cell depletion via CD20 mAbs can occur under different mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis (1-4). Many ongoing studies are focused on combination therapies with CD20 mAbs as an addition to chemotherapy, B cell receptor (BCR) signaling inhibitors, or BH3 mimetics (1,2,4). Additionally, the effects of bispecific antibodies and CD20 chimeric antigen receptor (CAR) T cell therapies are under investigation for the treatment of B cell malignancies (4,5).

References

1. Pavlasova G, Mraz M. The regulation and function of CD20: an "enigma" of B-cell biology and targeted therapy. Haematologica. 2020; 105(6):1494-1506. https://doi.org/10.3324/haematol.2019.243543

2. Payandeh Z, Bahrami AA, Hoseinpoor R, et al. The applications of anti-CD20 antibodies to treat various B cells disorders. Biomed Pharmacother. 2019; 109:2415-2426. https://doi.org/10.1016/j.biopha.2018.11.121

3. Margoni M, Preziosa P, Filippi M, Rocca MA. Anti-CD20 therapies for multiple sclerosis: current status and future perspectives. J Neurol. 2022; 269(3):1316-1334. https://doi.org/10.1007/s00415-021-10744-x

4. Klein C, Jamois C, Nielsen T. Anti-CD20 treatment for B-cell malignancies: current status and future directions. Expert Opin Biol Ther. 2021; 21(2):161-181. https://doi.org/10.1080/14712598.2020.1822318

5. Sharman JP. Targeting CD20: teaching an old dog new tricks. Hematology Am Soc Hematol Educ Program. 2019; 2019(1):273-278. https://doi.org/10.1182/hematology.2019000031

Bioinformatics

Entrez Mouse
Human
Rat
Human
Uniprot Human
Human
Human
Human
Human
Product By Gene ID 931
Alternate Names
  • B1
  • B-lymphocyte antigen CD20
  • B-lymphocyte cell-surface antigen B1
  • B-lymphocyte surface antigen B1
  • Bp35MGC3969
  • CD20 antigen
  • CD20 receptor
  • CD20S7
  • CVID5
  • LEU-16
  • Leukocyte surface antigen Leu-16
  • Membrane-spanning 4-domains subfamily A member 1
  • membrane-spanning 4-domains, subfamily A, member 1
  • MS4A2

Pathways for CD20

View related products by pathway and learn more about each of the pathways below.

Methylation
Histone Acetylation
Cell Differentiation
Dna Methylation
B Cell Differentiation
Pathogenesis

Research Areas for CD20

Find related products by research area and learn more about each of the different research areas below.

Adaptive Immunity
CD Markers
Cell Biology
Cytokine Research
Immunology
Signal Transduction
Stem Cell Markers

PTMs for CD20

Learn more about PTMs related to CD20.

Acetylation
Methylation

Bioinformatics Tool for CD20

Discover related pathways, diseases and genes to CD20. Need help? Read the Bioinformatics Tool Guide for instructions on using this tool.
 
Vizit™, under license from BioVista Inc.

Related CD20 Blog Posts

Check out the latest blog posts on CD20.
Antigen-loss relapse after successful CAR-T therapy; What do we do now?
By Jacqueline Carrico, BS, MD Tumor cell mechanisms driving tolerance to CAR-T Despite very promising results of CAR-T therapy in acute lymphoblastic leukemia, B-ALL, antigen-loss relapse has arisen as a major chall...    Read more.
CD20 (Cluster of differentiation 20, Membrane-spanning 4-domains subfamily A member 1 (MS4A1), CVID5, B-lymphocyte surface antigen B1)
CD20 is a human B-lymphocyte surface molecule that spans the membrane four times and is expressed on both normal and malignant cells.┬áThe CD20 antigen displays a unique expression pattern among hematopoietic cells - it is present on human pre B-ly...    Read more.
Read more CD20 related blogs.